Fibroblast growth factor 23 and uremic vascular calcification: Is it time to escalate from biomarker status to pathogenic agent?

Orson W. Moe; Makoto Kuro-O

doi:10.1038/ki.2013.471

Fibroblast growth factor 23 and uremic vascular calcification: Is it time to escalate from biomarker status to pathogenic agent?

Orson W. Moe, Makoto Kuro-O

Research output: Contribution to journal › Comment/debate › peer-review

6 Scopus citations

Abstract

Although epidemiologic associations have been informative, the elucidation of the role of fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) requires testing with robust experimental models. Jimbo et al. used animal and cell-culture models to query whether FGF23 is a direct 'vasculotoxin.' We discuss the interpretation of their findings. At this juncture, much remains unanswered about the significance of FGF23 elevation in CKD.

Original language	English (US)
Pages (from-to)	1022-1023
Number of pages	2
Journal	Kidney international
Volume	85
Issue number	5
DOIs	https://doi.org/10.1038/ki.2013.471
State	Published - May 2014

ASJC Scopus subject areas

Nephrology

Access to Document

10.1038/ki.2013.471

Cite this

@article{ffd985339b51497dab4059f467d8ec22,

title = "Fibroblast growth factor 23 and uremic vascular calcification: Is it time to escalate from biomarker status to pathogenic agent?",

abstract = "Although epidemiologic associations have been informative, the elucidation of the role of fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) requires testing with robust experimental models. Jimbo et al. used animal and cell-culture models to query whether FGF23 is a direct 'vasculotoxin.' We discuss the interpretation of their findings. At this juncture, much remains unanswered about the significance of FGF23 elevation in CKD.",

author = "Moe, {Orson W.} and Makoto Kuro-O",

year = "2014",

month = may,

doi = "10.1038/ki.2013.471",

language = "English (US)",

volume = "85",

pages = "1022--1023",

journal = "Kidney international",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Fibroblast growth factor 23 and uremic vascular calcification

T2 - Is it time to escalate from biomarker status to pathogenic agent?

AU - Moe, Orson W.

AU - Kuro-O, Makoto

PY - 2014/5

Y1 - 2014/5

N2 - Although epidemiologic associations have been informative, the elucidation of the role of fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) requires testing with robust experimental models. Jimbo et al. used animal and cell-culture models to query whether FGF23 is a direct 'vasculotoxin.' We discuss the interpretation of their findings. At this juncture, much remains unanswered about the significance of FGF23 elevation in CKD.

AB - Although epidemiologic associations have been informative, the elucidation of the role of fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) requires testing with robust experimental models. Jimbo et al. used animal and cell-culture models to query whether FGF23 is a direct 'vasculotoxin.' We discuss the interpretation of their findings. At this juncture, much remains unanswered about the significance of FGF23 elevation in CKD.

UR - http://www.scopus.com/inward/record.url?scp=84899708905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899708905&partnerID=8YFLogxK

U2 - 10.1038/ki.2013.471

DO - 10.1038/ki.2013.471

M3 - Comment/debate

C2 - 24786878

AN - SCOPUS:84899708905

SN - 0085-2538

VL - 85

SP - 1022

EP - 1023

JO - Kidney international

JF - Kidney international

IS - 5

ER -

Fibroblast growth factor 23 and uremic vascular calcification: Is it time to escalate from biomarker status to pathogenic agent?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this